Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone

Meletios Athanasios Dimopoulos, Katja Christina Weisel, Kevin W Song, Michel Delforge, Lionel Karlin, Hartmut Goldschmidt, Philippe Moreau, Anne Banos, Albert Oriol, Laurent Garderet, Michele M Cavo, Valentina Ivanova, Adrian Alegre, Joaquin Martinez-Lopez, Christine Chen, Andrew Spencer, Stefan Knop, Nizar Jacques Bahlis, Christoph Renner, Xin YuKevin Hong, Lars Sternas, Christian Jacques, Mohamed Zaki, Jesus Fernando San Miguel

    Research output: Contribution to journalArticleResearchpeer-review

    76 Citations (Scopus)


    Patients with refractory or relapsed and refractory multiple myeloma who no longer receive benefit from novel agents have limited treatment options and short expected survival. del(17p) and t(4;14) are correlated with shortened survival. The phase 3 MM-003 trial demonstrated significant progression-free and overall survival benefits from treatment with pomalidomide plus low-dose dexamethasone compared to high-dose dexamethasone among patients in whom bortezomib and lenalidomide treatment had failed. At an updated median follow-up of 15.4 months, the progression-free survival was 4.0 versus 1.9 months (HR, 0.50; P
    Original languageEnglish
    Pages (from-to)1327 - 1333
    Number of pages7
    Issue number10
    Publication statusPublished - 2015

    Cite this